Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
  • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
  • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings

Definitions

• This invention relates to a new process for producing optically active benzenesulfonamide derivatives which are represented by the following general formula (I) and are useful as antihypotensive agents and as intermediates for the manufacture of optically active drugs, wherein R1 and R2 are the same or different and selected independently from a hydrogen atom and lower alkyl groups; R3 is a hydrogen atom or a lower alkyl, hydroxyl or lower alkoxyl group; and R4 stands for a lower alkyl group.
• R1 and R2 are the same or different and selected independently from a hydrogen atom and lower alkyl groups; R3 is a hydrogen atom or a lower alkyl, hydroxyl or lower alkoxyl group; and R4 stands for a lower alkyl group.
• this invention provides a process for producing compounds of formula (I), which comprises decomposing a m-(2-substituted-alkylaminoalkyl)benzenesulfonamide derivative of formula (II) (wherein R1, R2, R3 and R4 are as defined above; R5 denotes a lower alkyl, a carboxy-lower-alkyl or a lower-alkoxycarbonyl-lower-alkyl group; and R6 is a substituted or unsubstituted phenyl group).
• the compounds (II) can best be prepared by reaction of sulfamoyl-substituted benzyl lower alkyl ketone (III) (wherein R1, R2, R3 and R4 are as defined above ), with optically active, substituted alkylamine (IV) (wherein R5 and R6 are as defined above ), in the presence of reducing agent.
• the term "lower” means, unless otherwise specified, linear or branched chains of 1 to 5 carbon atoms, preferably those containing no asymmetric carbon.
• lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl,isopentyl and neopentyl groups; and those of lower alkoxyl groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy and isopentyloxy groups.
• the lower alkyl represented by R5 is preferably methyl, ethyl, isopropyl or isobutyl, most preferably methyl.
• carboxy-lower-alkyl groups include carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl and carboxypentyl groups.
• esters of the above carboxy-lower-alkyls with a lower alkanol such as methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, isopropoxycarbonylmethyl, butoxycarbonylmethyl, isobutoxycarbonylmethyl, tert-butoxycarbonylmethyl, pentyloxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, isopropoxycarbonylethyl, butoxycarbonylethyl, isobutoxycarbonylethyl, tert-butoxycarbonylethyl, pentyloxycarbonylethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl
• “Decomposition” herein means a decomposition reaction in which R5-CH2-R6 or R5-CO-R6 is stereospecifically eliminated from a compound (II), which includes “hydrogenesis” by the action of a reducing agent
• R6 when R6 is a substituted phenyl, the substituent should be such a group that does not adversely affect the hydrogenesis with the elimination of R5-CH2-R6 but accelerates this elimination reaction.
• substituents include nitro and halogens such as bromine.
• Hydrogenesis is an advantageous method because it involves few reaction steps and high reaction and optical yields.
• R1, R2, R3, R4, R5 and R6 are as defined above and Ph denotes a substituted or unsubstituted phenyl).
• Compound (II) is prepared by condensation between compound (III) and compound (IV) in the presence of reducing agent.
• the reaction can be carried out in an organic solvent, such as methanol, ethanol or benzene, using the two reactants in nearly equimolar amounts ( or with a slight excess of either) one of them ), in the presence of lithium aluminum hydride, sodium cyanoborohydride, sodium borohydride or borane, or by catalytic reduction, under elevated pressure as required, in the presence of a catalyst such as Raney nickel, platinum/carbon, palladium/carbon and platinum oxide, or by electrolytic reduction using copper or platinum as cathode.
• organic solvent such as methanol, ethanol or benzene
• reaction temperature and time may vary depending on the type and quantity of reactants used, the type of reducing agent, pressure conditions and other factors. However, the reaction is generally carried out at room temperature or at elevated temperature, preferably at about 40 to 80°C, for 1 to 48 hours under normal pressure and for a shorter time under an elevated pressure.
• the pressure, if applied, is generally 1 to 100 atm, preferably 2 to 20 atm.
• reaction of this step preferentially gives a compound (II) in which the absolute conformation around the asymmetric carbon bonded to R4 is the same as that around the asymmetric carbon bonded to R5 and R6 in the compound (IV) used as reactant.
• the reaction preferentially gives R,R-isomer or S,S-isomer.
• a compound (II) obtained in Step 1 can be converted to the corresponding compound (I) or a salt thereof by hydrogenesis.
• Hydrogenesis is generally effected in a solvent, such as methanol or ethanol, by catalytic reduction using a theoretical amount of hydrogen gas in the presence of palladium/carbon as catalyst under elevated pressure as required. Catalytic reduction is most advantageous in this case because the final product can be obtained with a nearly quantitative yield.
• This reaction is carried out at room temperature or at elevated temperature, preferably at 40 to 80°C.
• the reaction time which depends on various reaction conditions, is generally 1 to 48 hours under normal pressure and is shorter under elevated pressure.
• the pressure, when applied, is usually from 1 to 100 atm.
• the absolute conformation around the asymmetric carbon in the compound (I) thus obtained is identical to that around the asymmetric carbon bonded to R4 in the compound (II), whether the two asymmetric carbon atoms in the compound (II) have same or different absolute conformation.
• the compounds prepared by the method described above can be isolated and purified by commonly used chemical operations, such as filtration, crystallization and recrystallization.
• optically active benzenesulfonamide derivatives (I) are useful as antihypotensive agents and as intermediates for the manufacture of adrenergic receptor ⁇ -blocking agents having a side chain, at the meta position which are described in Japanese Patent Publications No.11O665 (1981) and No.136561 (1982).
• the process of this invention is capable of producing optically active benzenesulfonamide derivatives (I) of high optical purity with higher reaction yield and optical yield, compared with the conventional method.
• the overall yield although somewhat different depending on the synthetic route and reaction conditions, is about 51.3% for hydrochloride and about 43.0% for free base under optimum conditions a 4 to 5 times higher than by the conventional method.
• the process of this invention is simple in operation because of the few reaction steps involved, and still higher yields can be achieved by optimum selection of reaction conditions.
• the reactions involved proceed very smoothly even under mild conditions and use of reactants in larger quantities does not lead to drop in yield, making the process of this invention suitable for commercial production.
• Compounds having adrenergic receptor ⁇ -blocking effect can be derived from a compound (I) according to the reaction given below, (wherein R1, R2, R3 and R4 are as defined above; X is a radical or a formyl group; Hal denotes a halogen atom; R8, R10 and R11 are selected independently from a hydrogen atom and lower alkyl groups; Y is a methylene group or oxygen atom; and R9 is a hydrogen atom or a lower alkyl, lower alkoxyl or lower alkenyloxy group ).
• the halogen atom Hal may be iodine, bromine or chlorine
• the lower alkenyloxy group R9 is, for example, vinyloxy, allyloxy, butenyloxy, isobutenyloxy or pentenyloxy.
• optically active m-(substituted-aminoalkyl)benzene-sulfonamides (VII) having adrenergic ⁇ -blocking effect and useful as antihypertensive agents can be prepared by reaction of compound (I) ( in the form of free base ) with halide (IV), or by reductive condensation between compound (1) ( free base ) and formyl derivative of compound (VI).
• the carbon atom to which R8 is bonded and that to which R10 and R11 are bonded are not asymmetric carbon atoms. If either one of these is asymmetric an optically active compound (VI) previously isolated should be used for the reaction.
• X in compound (VI) is the reaction is preferably carried out in the absence of solvent or in an organic solvent (e.g., benzene, toluene, xylene, dimethylformamide, dichloromethane, dichloroethane, methanol or ethanol ) at room temperature, at elevated temperature or under reflux, using an equal or slight molar excess amount of compound (VI).
• an organic solvent e.g., benzene, toluene, xylene, dimethylformamide, dichloromethane, dichloroethane, methanol or ethanol
• secondary or tertiary amine e.g., pyridine, picoline, N,N-dimethylaniline, N-methylmorpholine, trimethylamine, triethylamine or dimethylamine
• inorganic base e.g., potassium carbonate, sodium carbonate or sodium bicarbonate
• the reaction was terminated by addition of 50 ⁇ l methanol, and the reaction mixture was subjected to high-performance liquid chromatography [ column: Nucleosyl® 5 C18, 305cm x 4.6mm ID; column temperature: room temperature; mobile phase: acetonitrile/methanol/0.01M KH2PO4 solution ( 50:150:40 v/v ); flow speed: 1 ml/min; UV detector: ⁇ , 284 nm )].
• the optical purity of (R)-(-)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide hydrochloride showing a retention time of 20 minutes was 99.8% or higher.
• the separated oily material was extracted with ethyl acetate, and the extract solution was washed with saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate.
• the solution was subjected to distillation, and the residue was subjected to silica gel column chromatography, eluted with chloroform-methanol (9:5) to give 1.5 g of crude crystals.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Parent Applications (3)

Publications (2)

Family

ID=15939091

Family Applications (2)

Family Applications After (1)

Country Status (8)

Cited By (1)

Families Citing this family (27)

Family Cites Families (3)

• 1986
  • 1986-07-21 JP JP61172285A patent/JPH066565B2/ja not_active Expired - Lifetime
• 1987
  • 1987-07-20 KR KR1019870007809A patent/KR960003810B1/ko not_active IP Right Cessation
  • 1987-07-20 CA CA000542529A patent/CA1340332C/en not_active Expired - Lifetime
  • 1987-07-20 IE IE196087A patent/IE63344B1/en not_active IP Right Cessation
  • 1987-07-21 EP EP90104584A patent/EP0380144B1/en not_active Expired - Lifetime
  • 1987-07-21 EP EP87306453A patent/EP0257787B1/en not_active Expired - Lifetime
  • 1987-07-21 ES ES90104584T patent/ES2062136T3/es not_active Expired - Lifetime
  • 1987-07-21 ES ES198787306453T patent/ES2029838T3/es not_active Expired - Lifetime
  • 1987-07-21 DE DE90104584T patent/DE3788878T2/de not_active Expired - Lifetime
  • 1987-07-21 AT AT87306453T patent/ATE62667T1/de not_active IP Right Cessation
  • 1987-07-21 DE DE8787306453T patent/DE3769399D1/de not_active Expired - Lifetime
• 1990
  • 1990-03-10 AT AT90104584T patent/ATE100444T1/de not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events